Join our daily newsletter At The Bell to receive exclusive market insights
- Argenica Therapeutics (AGN) appoints CEO Dr Liz Dallimore as Managing Director, effective immediately
- Dr Dallimore is a research and development, innovation and commercialisation specialist and was most recently a Director of the WA Data Science Innovation Hub
- She has also held senior roles in management consulting with the likes of KPMG, Ernst & Young and PricewaterhouseCoopers
- Argenica has also appointed Dr Meghan Thomas as Head of Clinical Development where she will oversee the company’s clinical trial programs
- Shares in Argenica are up 3.03 per cent and are trading at 68 cents
Argenica Therapeutics (AGN) has appointed CEO Dr Liz Dallimore as Managing Director, effective immediately.
Dr Dallimore is a research and development, innovation and commercialisation specialist with more than 20 years of experience.
Prior to joining Argenica, she was the Director of the WA Data Science Innovation Hub.
She has also held senior roles in management consulting and was most recently KPMG’s National Director of Research Engagement and Commercialisation.
Before this, Dr Dallimore was with Ernst & Young and PricewaterhouseCoopers.
“I am delighted to join the Board of Argenica. As a company and team we are extremely excited about the potential for ARG-007 in ischaemic stroke, and the other applications we are pursuing,” Dr Dallimore said.
“We look forward to commencing the Phase 1 clinical trial shortly, and moving our lead
candidate forward through clinical development.”
Argenica has also appointed Dr Meghan Thomas as Head of Clinical Development.
In this role Dr Thomas will oversee Argenica’s clinical trial programs which includes the upcoming phase one clinical trial of ARG-007.
Currently, she is Vice President of Clinical Programs and Operations at Zelira Therapeutics (ZLD).
“Liz’s deep understanding of neuroscience, combined with her extensive commercial acumen, has been invaluable to Argenica,” Chairman Geoff Pocock said.
“We look forward to Liz’s ongoing leadership as the company moves into the clinic, which is an incredibly exciting time for the company.
“We also welcome Meghan to Argenica and very much look forward to her expertise and contribution she will make.”
Shares in Argenica were up 3.03 per cent and were trading at 68 cents at 2:02 pm AEST.
